X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Huadong will receive license for both the cream and foam formulations of topical Zoryve (roflumilast), a next generation PDE4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Arcutis Biotherapeutics
Deal Size: $94.2 million Upfront Cash: $30.0 million
Deal Type: Collaboration August 10, 2023
Details:
Under the terms of the exclusive licensing agreement, Huadong will advance research and development costs for Ashvattha’s hydroxyl dendrimer clinical candidates, OP-101, D-4517.2 and OP-801, and for additional preclinical candidates.
Lead Product(s): Dendrimer N-acetyl-cysteine
Therapeutic Area: Infections and Infectious Diseases Product Name: OP-101
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Ashvattha Therapeutics
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 27, 2022
Details:
CT053 (zevorcabtagene autoleucel), is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM).
Lead Product(s): Zevorcabtagene Autoleucel
Therapeutic Area: Oncology Product Name: CT053
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: CARsgen Therapeutics
Deal Size: $181.3 million Upfront Cash: $29.6 million
Deal Type: Collaboration January 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
